Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
P/E ratio for Nkarta, Inc. (NKTX)
P/E ratio as of 2023: -2.75
According to Nkarta, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.75. At the end of 2022 the company had a P/E ratio of -2.19.
P/E ratio history for Nkarta, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.75 |
| 2022 | -2.19 |
| 2021 | -6.01 |
| 2020 | -38.77 |
| 2019 | -18.80 |
| 2018 | -877198.21 |